Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease

Glycolysis-enhancing α1-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease

Abstract Terazosin is an α1-adrenergic receptor antagonist that enhances glycolysis and increases cellular ATP by binding to the enzyme phosphoglycerate kinase 1 (PGK1). Recent work has shown that terazosin is protective against motor dysfunction in rodent models of Parkinson’s disease (PD) and is a...

Full description

Bibliographic Details
Main Authors: Matthew A. Weber, Kartik Sivakumar, Ervina E. Tabakovic, Mayu Oya, Georgina M. Aldridge, Qiang Zhang, Jacob E. Simmering, Nandakumar S. Narayanan
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-023-00477-1

Internet

https://doi.org/10.1038/s41531-023-00477-1

Similar Items